ADC Therapeutics (ADCT) is down -8.9%, or -31c to $3.17.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADCT:
- ADC Therapeutics announces data from LOTIS-7 Phase 1b open-label clinical trial
- ADC Therapeutics: Updated data from Phase 2 Zynlonta study published in Lancet
- Molson Coors upgraded, Rivian downgraded: Wall Street’s top analyst calls
- ADC Therapeutics Highlights Q3 Advances and Strategic Focus
- ADC Therapeutics initiated with an Overweight at Stephens